Follicle-Stimulating Hormone Exacerbates Cardiovascular Disease in the Presence of Low or Castrate Testosterone Levels.

Follicle-Stimulating Hormone Exacerbates Cardiovascular Disease in the Presence of Low or Castrate Testosterone Levels.

Duivenvoorden, Wilhelmina C M; Margel, David; Subramony Gayathri, Vishal; Duceppe, Emmanuelle; Yousef, Sadiya; Naeim, Magda; Khajehei, Mohammad; Hopmans, Sarah; Popovic, Snezana; Ber, Yaara; Heels-Ansdell, Diane; Devereaux, Philip J; Pinthus, Jehonathan H.

Afiliação

Duivenvoorden WCM; Department of Surgery, Division of Urology, Faculty of Medicine, McMaster University, Hamilton, Ontario, Canada.
Margel D; Research Institute of St. Joe's Hamilton, Hamilton, Ontario, Canada.
Subramony Gayathri V; Department of Urology, Rabin Medical Center, Petach Tikva, Israel.
Duceppe E; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Yousef S; Research Institute of St. Joe's Hamilton, Hamilton, Ontario, Canada.
Naeim M; Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.
Khajehei M; Department of Medicine, Centre Hospitalier de l'Universite de Montréal, Montréal, Québec, Canada.
Hopmans S; Research Institute of St. Joe's Hamilton, Hamilton, Ontario, Canada.
Popovic S; Research Institute of St. Joe's Hamilton, Hamilton, Ontario, Canada.
Ber Y; Department of Surgery, Division of Urology, Faculty of Medicine, McMaster University, Hamilton, Ontario, Canada.
Heels-Ansdell D; Department of Surgery, Division of Urology, Faculty of Medicine, McMaster University, Hamilton, Ontario, Canada.
Devereaux PJ; Department of Pathology and Molecular Medicine, Faculty of Medicine, McMaster University, Hamilton, Ontario, Canada.
Pinthus JH; Department of Urology, Rabin Medical Center, Petach Tikva, Israel.

JACC Basic Transl Sci ; 9(3): 364-379, 2024 Mar.

Article em En | MEDLINE | ID: mdl-38559622

ABSTRACT

Low testosterone (T), common in aging men, associates with cardiovascular disease. We investigated whether follicle-stimulating hormone (FSH), which is affected by T, modulates the cardiovascular effects associated with low T or castration. FSHß-/-low-density lipoprotein receptor (LDLR)-/- mice, untreated or castrated (orchiectomy, gonadotropin-releasing hormone agonist or antagonist), demonstrated significantly less atherogenesis compared with similarly treated LDLR-/- mice, but not following FSH delivery. Smaller plaque burden in LDLR-/- mice receiving gonadotropin-releasing hormone antagonists vs agonists were nullified in FSHß-/-LDLR-/- mice. Atherosclerotic and necrotic plaque size and macrophage infiltration correlated with serum FSH/T. In patients with prostate cancer, FSH/T following androgen-deprivation therapy initiation predicted cardiovascular events. FSH facilitates cardiovascular disease when T is low or eliminated.

Palavras-chave

GnRH-antagonist; androgen-deprivation therapy; cardiovascular disease; follicle-stimulating hormone; prostate cancer

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article